Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2026)

Aquestive Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 16.25% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $46.0 million (down 13.69% YoY), while the FY2025 annual figure was $11.2 million, down 15.51% from the prior year.
• Non-Current Assets was $10.9 million for Q1 2026 at Aquestive Therapeutics, down from $11.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $17.6 million in Q1 2023 to a low of $10.9 million in Q1 2026.
• Historically, Non-Current Assets has averaged $14.2 million across 5 years, with a median of $13.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 34.37% in 2023, then retreated 21.21% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $17.2 million in 2022, then slipped by 4.25% to $16.5 million in 2023, then slipped by 19.74% to $13.2 million in 2024, then retreated by 15.51% to $11.2 million in 2025, then decreased by 1.92% to $10.9 million in 2026.
• The last three Non-Current Assets figures came in at $10.9 million (Q1 2026), $11.2 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.